DRAinh-A250
DRAinh-A250 is an orally active inhibitor of mouse and human SLC26A3 (DRA). DRAinh-A250 inhibits SLC26A3-mediated anion transport, blocks colonic fluid absorption, reduces luminal fluid alkalization in the distal colonic loops of mice, and alleviates Loperamide (HY-156131)-induced constipation in wild-type and cystic fibrosis mice. DRAinh-A250 can be used in the research of constipation and cystic fibrosis-related constipation.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 858747-13-4
- Formel: C20H17BrO5
- Molecular Weight:417.26
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
0.25 μM
|
Inhibition of human SLC26A3-mediated Cl-/I- exchange in HEK cells using YFP halide sensor.
Inhibition of human SLC26A3-mediated Cl-/I- exchange in HEK cells using YFP halide sensor.
|
30046015 |
DRAinh-A250 (compound 4ba) (0.001-1 μM) potently inhibits slc26a3-mediated chloride/iodide exchange in Fischer rat thyroid cells expressing mouse slc26a3 and halide-sensitive yellow fluorescent protein, with an IC50 of 0.15 μM[1].
DRAinh-A250 (0.02-12.5 μM) potently inhibits mouse slc26a3-mediated Cl−/HCO3− exchange in FRT cells, with an IC50 of approximately 0.1 μM[2].
DRAinh-A250 (0.01-3 μM) inhibits Cl−/SCN− exchange mediated by mouse slc26a3 in FRT cells, with an IC50 of approximately 0.3 μM[2].
DRAinh-A250 (1 μM; 0-5 min for inhibition kinetics, 10 min for reversibility washout) rapidly inhibits mouse slc26a3-mediated Cl−/I− exchange in FRT-YFP-slc26a3 cells[2].
DRAinh-A250 (0.156-1.25 μM) potently inhibits human SLC26A3-mediated Cl−/I− exchange in HEK cells, with an IC50 of approximately 0.25 μM[2].
DRAinh-A250 (10 μM; 24 h) shows no cytotoxicity to T84 cells after 24-hour incubation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:T84 cells
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Did not cause toxicity in T84 cells.
DRAinh-A250 (5 mg/kg; p.o.; single dose) partially reverses loperamide-induced constipation in wild-type mice and significantly alleviates loperamide-induced constipation in cystic fibrosis mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:wild-type; cystic fibrosis mice with loss of functional CFTR[2]
-
Dosage:5 mg/kg
-
Administration:p.o.; single dose
-
Result:Partially prevented Loperamide-induced reductions in stool weight, pellet number, and stool water content in wild-type mice.
Significantly increased stool weight, pellet number, and stool water content compared to Loperamide-only treated cystic fibrosis mice, reducing Loperamide-induced constipation.
Demonstrated fully reversible anticonstipation effect, with Loperamide-induced constipation remaining intact when administered 24 hours after treatment.
Chemical Information
-
CAS. Nr. 858747-13-4
-
Molecular Weight 417.26
-
Formel C20H17BrO5
-
SMILES
O=C1OC2=C(C=CC(OCC=3C=CC=C(Br)C3)=C2C)C(=C1CC(=O)O)C
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
DRAinh-A250 Related Classifications
HY-124706 Related Classifications
Powered by Bioz